Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM’s Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years
Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM’s Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2016
Συγγραφείς:
Gavriatopoulou, Maria Garcia-Sanz, Ramon Kastritis, Efstathios Morel, Pierre Kyrtsonis, Marie-Christine Michalis, Evridiki Kartasis, Zafeirios Leleu, Xavier Palladini, Giovanni Tedeschi, Alessandra others
